Eintrag weiter verarbeiten
Long-Term Follow-up of Patients with Chronic Myeloid Leukemia Having Received Autologous Stem Cell Transplantation.
Gespeichert in:
| Zeitschriftentitel: | Blood |
|---|---|
| Personen und Körperschaften: | , |
| In: | Blood, 114, 2009, 22, S. 4268-4268 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Hematology
|
| Schlagwörter: |
| Zusammenfassung: | <jats:title>Abstract</jats:title> <jats:p>Abstract 4268</jats:p> <jats:p>Before the introduction of imatinib mesylate, the median survival of chronic myeloid leukemia (CML) patients was approximately 60 months and the standard treatment with interferon-alpha (IFN-α) resulted in major cytogenetic responses of 20-25 %. As an alternative treatment approach at that time, intensive chemotherapy followed by autologous hematopoietic stem cell transplantation (autoHSCT) was investigated with the rational of debulking disease burden and mobilisation and transplantation of Philadelphia chromosome-negative (Ph-) stem cells. In the era of tyrosine kinase inhibitors (TKIs) as state-of-the-art therapy for CML, the concept of autoHSCT has attracted only little interest and long-term follow-up and outcome data after autoHSCT in CML patients is scarce.</jats:p> <jats:p>In this long-term analysis, we report on 21 CML patients, mobilized in early chronic phase (ECP) and transplanted with largely Ph- grafts, who received interferon alpha (IFNα) as maintenance. Imatinib mesylate was given upon cytogenetic relapse or disease progression after IFN-α. The 10-year survival was 61% and 11 patients (52%) were alive at a median follow-up of 12.5 years (range 0.3 - 13.8) with 8 patients in complete hematologic remission (CHR) and 3 of 8 in major molecular remission (MMR). While all patients in MMR and 2 of 5 patients in CHR received imatinib, it is noteworthy that three patients remaining in CHR only received IFN-α maintenance after autoHSCT.</jats:p> <jats:p>With the limitations of a small patient population, this is the longest follow-up analysis demonstrating that autoHSCT in CML is very efficient to debulk the disease and able to induce major and sustained molecular responses in the majority of patients with substantial long-term survival rates.</jats:p> <jats:sec> <jats:title>Disclosures:</jats:title> <jats:p>Waller: Hospira UK Ltd: Consultancy.</jats:p> </jats:sec> |
|---|---|
| Umfang: | 4268-4268 |
| ISSN: |
0006-4971
1528-0020 |
| DOI: | 10.1182/blood.v114.22.4268.4268 |